Compare · AVTR vs FLDM
AVTR vs FLDM
Side-by-side comparison of Avantor Inc. (AVTR) and Fluidigm Corporation (FLDM): market cap, price performance, sector, and recent activity on the wire.
Summary
- AVTR operates in Industrials, while FLDM operates in Capital Goods - the two are in different parts of the market.
- AVTR is the larger of the two at $6.25B, about 25.6x FLDM ($244.6M).
- AVTR has hit the wire 3 times in the past 4 weeks while FLDM has been quiet.
- AVTR has more recent analyst coverage (25 ratings vs 0 for FLDM).
- Company
- Avantor Inc.
- Fluidigm Corporation
- Price
- $9.73+6.28%
- $3.70-7.27%
- Market cap
- $6.25B
- $244.6M
- 1M return
- +17.01%
- -
- 1Y return
- -27.65%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2011
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 0
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Fluidigm Corporation
Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has a collaboration agreement with the Karolinska Institutet for research applications and product development utilizing CyTOF XT. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Latest AVTR
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Murthy Mala was granted 25,270 shares, increasing direct ownership by 57% to 69,479 units (SEC Form 4)
- Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)
- Director Dingemans Simon was granted 25,270 shares, increasing direct ownership by 406% to 31,495 units (SEC Form 4)
- Director Massaro Joseph R was granted 25,270 shares, increasing direct ownership by 48% to 77,408 units (SEC Form 4)
- Director Makin Louise was granted 25,270 shares, increasing direct ownership by 116% to 47,140 units (SEC Form 4)
Latest FLDM
- No More Free COVID-19 At-Home Tests, Federal Government Says
- Fluidigm Corporation filed SEC Form 8-K: Leadership Update
- Fluidigm Corporation filed SEC Form 8-K: Leadership Update
- SEC Form 4: Colston Bill was granted 30,914 shares, increasing direct ownership by 109% to 59,288 units
- SEC Form 4: Burbach Gerhard F was granted 30,914 shares, increasing direct ownership by 47% to 96,827 units
- SEC Form 4: Madaus Martin D was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Witney Frank was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Paya Carlos V was granted 30,914 shares, increasing direct ownership by 44% to 100,468 units
- SEC Form 4: Casdin Eli was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Clague Laura was granted 30,914 shares, increasing direct ownership by 65% to 78,415 units